As of 2015, multiple sclerosis (MS) is the only treatable neurodegenerative disease. It has frequent visual manifestations, most of which are in the clinical purview of neuro-ophthalmologists. This syllabus is intended to update neuro-ophthalmologists about new data surrounding, the new and emerging disease modifying therapies, and the use of targeted symptomatic therapies available for treatment of common neuro-ophthalmologic complaints experienced by patients living with MS.
Relation is Part of
NANOS Annual Meeting Journal Club, 2015
Ari J. Green, MD, University of California San Francisco
Spencer S. Eccles Health Sciences Library, University of Utah